Clinical Trial Diversity Action Plans Need Timely US FDA Feedback, Groups Say

Industry organizations argued feedback should be expected and object to draft guidance language suggesting it may be optional. The agency also should apply waiver criteria flexibly and address potential consequences if enrollment goals are not met, stakeholders say.